University of California

Fred Hutchinson Cancer Center

Rebecca J Abergel

Gauthier J P Deblonde

Ilya Captain

Kenneth N Raymond

Roland K Strong

Peter Rupert

David K Shuh

Taylor A Choi

Julian Rees

Peter Agbo

Abel Ricano

Gauthier Jp Deblonde

Gauthier J Deblonde

Provided herein are a variety of metal chelators as well as methods of use thereof.

Compositions of chelating molecules

Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Chelating platform for delivery of radionuclides

Provided herein are separation processes for metal ions present in aqueous solutions based on methods involving liquid-liquid extraction. The separation process involves a chelator that can selectively bind to at least one of the metals at a relatively low pH. This can be used, for example, for recovery and purification of actinides from lanthanides, separation of metal ions based on their valence, and separation of metal ions based on the pH of the extraction conditions.

Separation of metal ions by liquid-liquid extraction

Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

Embodiments relate generally to lanthanide nanocrystals as ultraviolet downconverters.

Growing community of inventors

Kensington, CA, United States of America

Rebecca J Abergel